In Europe, treatment options for SMA patients with four SMN2 copies include SMN-targeted therapies such as nusinersen and risdiplam, both of which have been shown in clinical trials to increase SMN protein levels and improve motor function. Here, SMN2 is linked to proximal spinal muscular atrophy.